S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 38 of 38

Issue Date	Title / Author(s) / Citation	File
2011	Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma Cho, Young-Ah; Yoon, Hye-Jung; Lee, Jae-Il; Hong, Sam-Pyo; Hong, Seong-Doo Oral Oncology; Vol.47, No.12, pp.1148-1153	DOI
2011-02	구강 편평세포암종에서 PD-L1의 발현과 종양침윤림프구와의 관계 조영아	link
2016-03	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma Ock, Chan-Young; Kim, Sehui; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Jin-Ho; Jeon, Yoon Kyung; Lee, Ju-Seog; Kwon, Seong Keun; Hah, J. Hun; Kwon, Tack-Kyun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung-Whun; Heo, Dae Seog Oncotarget, Vol.7 No.13, pp.15901-15914	view file DOI
2016-04	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Perez-Gracia, Jose L.; Han, Ji-Youn; Molina, Julian; Kim, Joo-Hang; Arvis, Catherine Dubos; Ahn, Myung-Ju; Majem, Margarita; Fidler, Mary J.; de Castro, Gilberto, Jr.; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B. The Lancet, Vol.387 No.10027, pp.1540-1550	DOI
2016-10	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma Kim, Ryul; Keam, Bhumsuk; Kwon, Dohee; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Hak Jae; Jeon, Yoon Kyung; Park, In Kyu; Kang, Chang Hyun; Kim, Dong-Wan; Kim, Young Tae; Heo, Dae Seog World Journal of Gastroenterology, Vol.22 No.37, pp.8389-8397	view file DOI
2017-05	Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ Lim, Chae-Lyul; Lee, Yeon-Ju; Cho, Jong-Ho; Choi, Heonsik; Lee, Bumsup; Lee, Myung Chul; Kim, Sujeong BMC Musculoskeletal Disorders, 18(1):199	view file link
2017-08	Development of Immunocytokine Based on Human PD-L1 Antibody and Interferon-β-1b Mutein 이상윤	view file
2017-09	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release Suh, Koung Jin; Sung, Ji Hea; Kim, Jin Won; Han, Song-Hee; Lee, Hye Seung; Min, Ahrum; Kang, Mi Hyun; Kim, Ji Eun; Kim, Ji-Won; Kim, Se Hyun; Lee, Jeong-Ok; Kim, Yu Jung; Lee, Keun-Wook; Kim, Jee Hyun; Bang, Soo-Mee; Im, Seock-Ah; Lee, Jong Seok Oncotarget, Vol.8 No.38, pp.63901-63910	DOI
2017-09	Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma Ahn, Hyein; Yang, Jeong Mi; Kim, Hyojin; Chung, Jin-Haeng; Ahn, Soon-Hyun; Jeong, Woo-Jin; Paik, Jin Ho Oncotarget, Vol.8 No.39, pp.66178-66194	DOI
2018-02	Comprehensive analysis of molecular characteristics and tumor immune microenvironment in stage II and III gastric carcinoma 고지원	view file
2018-02	Radiation-induced change of PD-1/PD-L1 immune checkpoint in mouse and human colorectal cancer models 임유진	view file
2018-03	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012 Tahara, Makoto; Muro, Kei; Hasegawa, Yasuhisa; Chung, Hyun Cheol; Lin, Chia-Chi; Keam, Bhumsuk; Takahashi, Kenichi; Cheng, Jonathan D.; Bang, Yung-Jue Cancer Science, Vol.109 No.3, pp.771-776	DOI
2018-10	Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300 Bang, Y. -J.; Ruiz, E. Yanez; Van Cutsem, E.; Lee, K. -W.; Wyrwicz, L.; Schenker, M.; Alsina, M.; Ryu, M. -H.; Chung, H. -C.; Evesque, L.; Al-Batran, S. -E.; Park, S. H.; Lichinitser, M.; Boku, N.; Moehler, M. H.; Hong, J.; Xiong, H.; Hallwachs, R.; Conti, I.; Taieb, J. Annals of Oncology, Vol.29 No.10, pp.2052-2060	DOI
2018-11	Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma Kwon, Hyun Jung; Yang, Jeong Mi; Lee, Jeong-Ok; Lee, Jong Seok; Paik, Jin Ho Journal of Translational Medicine, Vol.16 No.1, p. 320	DOI
2019-01	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors Kim, Ryul; Keam, Bhumsuk; Kim, Sehui; Kim, Miso; Kim, Se Hyun; Kim, Jin Wook; Kim, Yu Jung; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Lee, Jong Seok; Heo, Dae Seog BMC Cancer, Vol.19 No.1, p. 19	view file DOI
2019-01	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer Johnston, Stephen; Martin, Miguel; Di Leo, Angelo; Im, Seock-Ah; Awada, Ahmad; Forrester, Tammy; Frenzel, Martin; Hardebeck, Molly C.; Cox, Joanne; Barriga, Susana; Toi, Masakazu; Iwata, Hiroji; Goetz, Matthew P. npj Breast Cancer, Vol.5 No.1, p. 5	DOI
2019-01	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial Keilholz, Ulrich; Mehnert, Janice M; Bauer, Sebastian; Bourgeois, Hugues; Patel, Manish R; Gravenor, Donald; Nemunaitis, John J; Taylor, Matthew H; Wyrwicz, Lucjan; Lee, Keun-Wook; Kasturi, Vijay; Chin, Kevin; von Heydebreck, Anja; Gulley, James L Journal for ImmunoTherapy of Cancer, 7(1):12	view file DOI
2019-02	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design Moehler, Markus; Ryu, Min-Hee; Dvorkin, Mikhail; Lee, Keun-Wook; Coskun, Hasan S.; Wong, Rachel; Chung, Hyun C.; Poltoratsky, Artem; Tsuji, Akihito; Yen, Chia Jui; Muntean, Alina S.; Le Sourd, Samuel; Vaccaro, Gina M.; Overton, Lindsay; Boku, Narikazu; Wainberg, Zev A.; Patel, Manish; Sharma, Maitreyi; Xiong, Huiling; Conti, Ilaria; Taieb, Julien; Bang, Yung-Jue Future Oncology, Vol.15 No.6, pp.567-577	DOI
2019-03	Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer Mehnert, Janice M; Varga, Andrea; Brose, Marcia S.; Aggarwal, Rahul R; Lin, Chia-Chi; Prawira, Amy; de Braud, Filippo; Tamura, Kenji; Doi, Toshihiko; Piha-Paul, Sarina A.; Gilbert, Jill; Saraf, Sanatan; Thanigaimani, Pradeep; Cheng, Jonathan D; Keam, Bhumsuk BMC Cancer. 2019 Mar 04;19(1):196	view file DOI
2019-03	A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors Fukamachi, Hiroshi; Kim, Seon-Kyu; Koh, Jiwon; Lee, Hye Seung; Sasaki, Yasushi; Yamashita, Kentaro; Nishikawaji, Taketo; Shimada, Shu; Akiyama, Yoshimitsu; Byeon, Sun-ju; Bae, Dong-Hyuck; Okuno, Keisuke; Nakagawa, Masatoshi; Tanioka, Toshiro; Inokuchi, Mikito; Kawachi, Hiroshi; Tsuchiya, Kiichiro; Kojima, Kazuyuki; Tokino, Takashi; Eishi, Yoshinobu; Kim, Yong Sung; Kim, Woo Ho; Yuasa, Yasuhito; Tanaka, Shinji Journal of Experimental & Clinical Cancer Research. 2019 Mar 12;38(1):127	view file DOI
2019-04	Dynamics of soluble programmed death-ligand 1 (SPDL1) during chemotherapy and its prognostic implications in cancer patients: Biomarker development in immuno-oncology Ha, Hyerim; Bang, Ju-Hee; Nam, Ah-Rong; Park, Ji-Eun; Jin, Mei Hua; Bang, Yung-Jue; Oh, Do-Youn Cancer Research and Treatment, Vol.51 No.2, pp.832-840	DOI
2019-05	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC Barlesi, Fabrice; Garon, Edward B.; Kim, Dong-Wan; Felip, Enriqueta; Han, Ji-Youn; Kim, Joo-Hang; Ahn, Myung-Ju; Fidler, Mary Jo; Gubens, Matthew A.; de Castro, Gilberto, Jr.; Surmont, Veerle; Li, Qiao; Deitz, Anne C.; Lubiniecki, Gregory M.; Herbst, Roy S. Journal of Thoracic Oncology, Vol.14 No.5, pp.793-801	DOI
2019-05	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report Yang, James Chih-Hsin; Shepherd, Frances A.; Kim, Dong-Wan; Lee, Gyeong-Won; Lee, Jong Seok; Chang, Gee-Chen; Lee, Sung Sook; Wei, Yu-Feng; Lee, Yun Gyoo; Laus, Gianluca; Collins, Barbara; Pisetzky, Francesca; Horn, Leora Journal of Thoracic Oncology, Vol.14 No.5, pp.933-939	DOI
2019-07	Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors Hellmann, M. D.; Kim, T. -W.; Lee, C. B.; Goh, B-C; Miller, W. H., Jr.; Oh, D. -Y.; Jamal, R.; Chee, C. -E.; Chow, L. Q. M.; Gainor, J. F.; Desai, J.; Solomon, B. J.; Das Thakur, M.; Pitcher, B.; Foster, P.; Hernandez, G.; Wongchenko, M. J.; Cha, E.; Bang, Y. -J.; Siu, L. L.; Bendell, J. Annals of Oncology, Vol.30 No.7, pp.1134-1142	DOI
2019-08	Therapeutic co-targeting of WEE1 and ATM downregulates PD-L1 expression in pancreatic cancer 김미화	view file link
2019-10	Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies Ahn, Soomin; Lee, Yangkyu; Kim, Ji-Won; Lee, Jong-Chan; Hwang, Jin-Hyeok; Yoon, Yoo-Seok; Cho, Jai Young; Han, Ho-Seong; Choi, YoungRok; Kim, Haeryoung Histopathology, Vol.75 No.4, pp.526-536	DOI
2020	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines Park, Ji-Eun; Kim, Seong-Eun; Keam, Bhumsuk; Park, Ha-Ram; Kim, Soyeon; Kim, Miso; Kim, Tae Min; Doh, Junsang; Kim, Dong-Wan; Heo, Dae Seog Journal for ImmunoTherapy of Cancer, Vol.8 No.2, p. e000873	view file DOI
2020-01	Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer Jin, Mei Hua; Nam, Ah-Rong; Park, Ji Eun; Bang, Ju-Hee; Bang, Yung-Jue; Oh, Do-Youn Cancer Research and Treatment, Vol.52 No.1, pp.149-166	view file DOI
2021	Comprehensive gene expression analyses of immunohistochemically defined subgroups of muscle-invasive urinary bladder urothelial carcinoma 김보현	view file link
2021-02	Tumor cell-intrinsic PD-L1 signal regulates cell proliferation and metastasis of head and neck cancer 안치현	link
2021-03	Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer Jung, Eun Hee; Jang, Hee Ryeong; Kim, Se Hyun; Suh, Koung Jin; Kim, Yu Jung; Lee, Ju-Hyun; Chung, Jin-Haeng; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Thoracic Cancer, Vol.12 No.5, pp.619-630	DOI
2021-08	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 Mansfield, Aaron S.; Herbst, Roy S.; de Castro, Gilberto; Hui, Rina; Peled, Nir; Kim, Dong-Wan; Novello, Silvia; Satouchi, Miyako; Wu, Yi-Long; Garon, Edward B.; Reck, Martin; Robinson, Andrew G.; Samkari, Ayman; Piperdi, Bilal; Ebiana, Victoria; Lin, Jianxin; Mok, Tony S.K. JTO Clinical and Research Reports, Vol.2 No.8, p. 100205	DOI
2021-09	Osmium-Tellurium Nanozymes for Pentamodal Combinatorial Cancer Therapy Kang, Seounghun; Gil, Yeong-Gyu; Yim, Gyeonghye; Min, Dal-Hee; Jang, Hongje ACS Applied Materials and Interfaces, Vol.13 No.37, pp.44124-44135	DOI
2021-10	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC Herbst, Roy S.; Garon, Edward B.; Kim, Dong-Wan; Cho, Byoung Chul; Gervais, Radj; Perez-Gracia, Jose L.; Han, Ji-Youn; Majem, Margarita; Forster, Martin D.; Monnet, Isabelle; Novello, Silvia; Gubens, Matthew A.; Boyer, Michael; Su, Wu-Chou; Samkari, Ayman; Jensen, Erin H.; Kobie, Julie; Piperdi, Bilal; Baas, Paul Research in Social and Administrative Pharmacy, Vol.16 No.10, pp.1718-1732	DOI
2022-01	Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma Lee, Ki Rim; Koh, Jiwon; Jeon, Yoon Kyung; Kwon, Hyun Jung; Lee, Jeong-Ok; Paik, Jin Ho Journal of Pathology and Translational Medicine, Vol.56 No.1, pp.32-39	DOI
2022-08	The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells Kwon, Yong-Jin; Seo, Eun-Bi; Jeong, Ae Jin; Lee, Song-Hee; Noh, Kum Hee; Lee, Sangsik; Cho, Chung-Hyun; Lee, Chang-Han; Shin, Hyun Mu; Kim, Hang-Rae; Moon, Hyeong-Gon; Ye, Sang-Kyu BMC Cancer, 22(1):852	view file link
2023-05	Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment Kwon, Hyun Jung; Park, Yujun; Nam, Soo Kyung; Kang, Enoch; Kim, Ka-Kyung; Jeong, Inhae; Kwak, Yoonjin; Yoon, Jeesun; Kim, Tae-Yong; Lee, Keun-Wook; Oh, Do-Youn; Im, Seock-Ah; Kong, Seong-Ho; Park, Do Joong; Lee, Hyuk-Joon; Kim, Hyung-Ho; Yang, Han-Kwang; Lee, Hye Seung Cancer Medicine, Vol.12 No.9, pp.1-14	DOI
2024-02	Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types Shen, Jeanne; Choi, Yoon-La; Lee, Taebum; Kim, Hyojin; Chae, Young Kwang; Dulken, Ben W.; Bogdan, Stephanie; Huang, Maggie; Fisher, George A.; Park, Sehhoon; Lee, Se-Hoon; Hwang, Jun-Eul; Chung, Jin-Haeng; Kim, Leeseul; Song, Heon; Pereira, Sergio; Shin, Seunghwan; Lim, Yoojoo; Ahn, Chang Ho; Kim, Seulki; Oum, Chiyoon; Kim, Sukjun; Park, Gahee; Song, Sanghoon; Jung, Wonkyung; Kim, Seokhwi; Bang, Yung-Jue; Mok, Tony S. K.; Ali, Siraj M.; Ock, Chan-Young Journal for ImmunoTherapy of Cancer, Vol.12 No.2, p. 008339	DOI